The chief drug company Dr Reddys has been given eight comments for the US drug regulator USFDA plant in its dub, Visakhapatnam.
USFDA started inspection of this plant of Dr. Reddy’s on October 22. The company has been assigned Form 483 with 8 comments. Explain that companies receiving comments from USFDA have to reply in writing in 15 days with corrective and preventive action plan.
Dr Reddy’s shares had a negative impact on the news. In the BSE, Dr Reddy’s shares opened at Rs 2,450.05 against the previous closing price of Rs 2,597.70. After the start of the fall, the stock remained in weak position. In the shares of the company, the transaction is going on at Rs. 2,452.05, with a loss of around 145.65 rupees or 5.61% at 10 o’clock in the morning.
Nse&Bse tips, Intraday tips is also the part of our advisory recommendations you can also know more if you are interested in Financial Trading click here subscribe us free>>Equity Service